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Mitochondrial energy metabolism
in heart failure: a question of balance
Janice M. Huss1,2 and Daniel P. Kelly1,2,3,4
1Center

for Cardiovascular Research and 2Department of Medicine, 3Department of Molecular Biology & Pharmacology, and
4Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.

The mitochondrion serves a critical role as a platform for energy transduction, signaling, and cell death pathways
relevant to common diseases of the myocardium such as heart failure. This review focuses on the molecular regulatory events and downstream effector pathways involved in mitochondrial energy metabolic derangements known
to occur during the development of heart failure.
Introduction
All cellular processes are driven by ATP-dependent pathways. The
heart has perpetually high energy demands related to the maintenance of specialized cellular processes, including ion transport,
sarcomeric function, and intracellular Ca2+ homeostasis. Myocardial workload (energy demand) and energy substrate availability
(supply) are in continual flux, yet the heart has a limited capacity for substrate storage. Thus, ATP-generating pathways must
respond proportionately to dynamic fluctuations in physiological demands and fuel delivery. The time frame of such metabolic
regulatory responses ranges from seconds to minutes (acute) or
hours to days (chronic) and involves regulation at multiple levels,
including allosteric control of enzyme activity via metabolic intermediates, signal transduction events, and the regulation of genes
encoding rate-limiting enzymes and proteins.
Metabolic regulation is inextricably linked with cardiac function. This metabolism-function relationship is relevant to diseases that lead to cardiac hypertrophy and heart failure. The
progression to heart failure of any cause is associated with a
gradual but progressive decline in the activity of mitochondrial
respiratory pathways leading to diminished capacity for ATP
production. Reduced capacity for energy transduction leads
to secondary dysregulation of cellular processes critical for
cardiac pump function, including Ca2+ handling and contractile function, which results in a downward spiral of increased
energy demand and diminished function. Evidence has emerged
that energy deficiency can be a cause and an effect of heart failure. Cardiac metabolic regulatory events may also be adaptive
in certain disease states. For example, in the ischemic heart, a
reduction in mitochondrial oxidative capacity serves to reduce
oxygen consumption in the context of limited O2 availability.
Many of the metabolic regulatory events that dictate fuel selection and capacity for ATP production in the normal and failing heart occur at the level of gene expression. The consequence
of specific metabolic gene regulatory events as adaptive versus
Nonstandard abbreviations used: Ant, adenine nucleotide translocator; BAT,
brown adipose tissue; ERR, estrogen-related receptor; FA, fatty acid; FADH2, reduced
flavin adenine dinucleotide; FAO, FA β-oxidation; NRF, nuclear respiratory factor;
PDH, pyruvate dehydrogenase; PET, positron emission tomography; PGC-1, PPARγ
coactivator-1; PRC, PGC-1–related coactivator; RXRα, retinoid X receptor α; TCA,
tricarboxylic acid; Tfam, mitochondrial transcription factor A.
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maladaptive in the context of myocardial disease is an area of
intense investigation.
The purposes of this review are to provide a brief overview of
cardiac energy metabolic pathways with emphasis on the mitochondrion, to describe the gene regulatory circuitry involved in
the regulation of cardiac mitochondrial energy metabolism in
the normal heart, to summarize the current knowledge about
how this metabolic regulatory network is altered during the
development of heart failure, and to review the evidence that
links altered energy metabolism to the development of heart
failure. Emphasis will be given to gene regulatory mechanisms
and upstream signaling pathways.
Cardiac energy metabolic pathways
Oxidation of fatty acids (FAs) and glucose in mitochondria
accounts for the vast majority of ATP generation in the healthy
adult heart (1, 2). FAs are the preferred substrate in the adult myocardium, supplying about 70% of total ATP (3–5). FAs derived
from circulating triglyceride-rich lipoproteins and albuminbound nonesterified FAs are oxidized in the mitochondrial matrix
by the process of FA β-oxidation (FAO), whereas pyruvate derived
from glucose and lactate is oxidized by the pyruvate-dehydrogenase (PDH) complex, localized within the inner mitochondrial
membrane (Figure 1). Acetyl-CoA, derived from both pathways,
enters the tricarboxylic acid (TCA) cycle. Reduced flavin adenine
dinucleotide (FADH2) and NADH are generated via substrate flux
through the β-oxidation spiral and the TCA cycle, respectively.
The reducing equivalents enter the electron transport chain,
producing an electrochemical gradient across the mitochondrial
membrane that drives ATP synthesis in the presence of molecular
oxygen (oxidative phosphorylation).
Mitochondrial enzymes are encoded by both nuclear and
mitochondrial genes (reviewed in ref. 6). All of the enzymes
of β-oxidation and the TCA cycle, and most of the subunits of
electron transport/oxidative phosphorylation, are encoded by
nuclear genes. The mitochondrial genome is comprised of 1 circular double-stranded chromosome that encodes 13 electron
transport chain subunits within complexes I, III, and IV (7).
Since mitochondrial number and function require both nuclear
and mitochondrial-encoded genes, coordinated mechanisms
exist to regulate the 2 genomes and determine overall cardiac
oxidative capacity. In addition, distinct pathways exist to coordinately regulate nuclear genes encoding component mitochondrial pathways.
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Figure 1
Pathways involved in cardiac energy metabolism. FA and glucose oxidation are the main
ATP-generating pathways in the adult mammalian heart. Acetyl-CoA derived from FA
and glucose oxidation is further oxidized in
the TCA cycle to generate NADH and FADH2,
which enter the electron transport/oxidative
phosphorylation pathway and drive ATP synthesis. Genes encoding enzymes involved at
multiple steps of these metabolic pathways
(i.e., uptake, esterification, mitochondrial
transport,and oxidation) are transcriptionally
regulated by PGC-1α with its nuclear receptor partners, including PPARs and ERRs (blue
text). Glucose uptake/oxidation and electron
transport/oxidative phosphorylation pathways
are also regulated by PGC-1α via other transcription factors, such as MEF-2 and NRF-1.
Cyt c, cytochrome c.

The transcriptional network regulating cardiac
mitochondrial biogenesis and respiratory function
PGC-1α: an inducible integrator of transcriptional circuits regulating mitochondrial biogenesis and function. The PPARγ coactivator-1 (PGC-1)
family of transcriptional coactivators is involved in regulating
mitochondrial metabolism and biogenesis. PGC-1α was the first
member discovered through its functional interaction with the
nuclear receptor PPARγ in brown adipose tissue (BAT), a mitochondrial-rich tissue involved in thermogenesis (8). Two PGC-1α–
related coactivators, PGC-1β (also called PERC) and PGC-1–related coactivator (PRC), have since been identified (9–11). PRC is ubiquitously expressed and coactivates transcription factors involved
in mitochondrial biogenesis; however, to date there is no direct
empirical evidence that PRC drives or is necessary for mitochondrial biogenesis (9, 12). PGC-1α and PGC-1β share some regulatory overlap. Both are preferentially expressed in tissues with high
oxidative capacity, such as heart, slow-twitch skeletal muscle, and
BAT, where they serve critical roles in the regulation of mitochondrial functional capacity (8, 10, 13–15). PGC-1α regulates additional metabolic pathways, including hepatic gluconeogenesis and
skeletal muscle glucose uptake (16–18). Based on its tissue expression pattern, PGC-1β probably plays a role in regulating energy
metabolism in the heart, although its precise role in the normal
heart and in mediating alterations in energy metabolism observed
in heart failure has not been investigated.
PGC-1α is distinct from other PGC-1 family members, indeed
from most coactivators, in its broad responsiveness to developmental alterations in energy metabolism and physiological and
pathological cues at the level of expression and transactivation. In
the heart, PGC-1α expression increases at birth coincident with
an increase in cardiac oxidative capacity and a perinatal shift from
548
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reliance on glucose metabolism to the oxidation of fats for energy
(19). PGC-1α is induced by physiological stimuli that increase ATP
demand and stimulate mitochondrial oxidation, including cold
exposure, fasting, and exercise (8, 19–23). Activation of the PGC-1α
regulatory cascade increases cardiac mitochondrial oxidative capacity in the heart. In cardiac myocytes in culture, PGC-1α increases
mitochondrial number, upregulates expression of mitochondrial
enzymes, and increases rates of FA oxidation and coupled respiration (19, 24). A mouse cardiac-specific conditional transgenic
expression system was used to demonstrate that PGC-1α triggers
mitochondrial biogenesis in vivo in a developmental stage–dependent manner: permissive during the neonatal period but less so in
the adult heart (25). In summary, PGC-1α is an inducible coactivator that coordinately regulates cardiac fuel selection and mitochondrial ATP-producing capacity.
How does PGC-1α exert its pleiotropic effects on mitochondrial
biogenesis and respiratory function? Recent work by several laboratories has provided insight into the downstream transcriptional
regulatory circuits through which PGC-1α mediates its effects
(Figure 2) (6). PGC-1α activates expression of nuclear respiratory factor-1 (NRF-1) and NRF-2 and directly coactivates NRF-1 on its target
gene promoters (13). NRF-1 and NRF-2 regulate expression of mitochondrial transcription factor A (Tfam), a nuclear-encoded transcription factor that binds regulatory sites on mitochondrial DNA and is
essential for replication, maintenance, and transcription of the mitochondrial genome (26–28). Furthermore, NRF-1 and NRF-2 regulate
the expression of nuclear genes encoding respiratory chain subunits
and other proteins required for mitochondrial function (29, 30).
PGC-1α coactivates the PPAR and ERR nuclear receptors, critical regulators of myocardial FA utilization. PGC-1α regulates genes involved in
the cellular uptake and mitochondrial oxidation of FAs through
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Figure 2
PGC-1α is an integrator of the transcriptional network regulating
mitochondrial biogenesis and function. Numerous signaling pathways, including Ca2+-dependent, NO, MAPK, and β-adrenergic
pathways (β3/cAMP), activate the PGC-1α directly by increasing
either PGC-1α expression or activity. Additionally, the p38MAPK
pathway selectively activates PPARα, which may bring about synergistic activation in the presence of PGC-1α, whereas ERK-MAPK
has the opposite effect. These signaling pathways transduce
physiological stimuli, such as stress, fasting, and exercise, to the
PGC-1α pathway. PGC-1α, in turn, coactivates transcriptional
partners, including NRF-1 and -2, ERRα, and PPARα, which
regulate mitochondrial biogenesis and FA-oxidation pathways.
Dashed lines indicate activation mediated by signal transduction
pathways in contrast to the coactivation by PGC-1α, which is
denoted by solid lines. The arrows from ERRα to the NRFs and
the PPAR complex indicate that ERRα activates these pathways
at the level of expression.

direct coactivation of PPARs and estrogen-related receptors (ERRs)
(Figure 2) (31–34). PPARs are FA-activated members of the nuclear
receptor superfamily of transcription factors that serve as central
regulators of cardiac FA metabolism. There are 3 PPAR isoforms
(α, β/δ, and γ); PPARα and PPARβ are the primary regulators of FA
metabolism in the heart. PPARs function by binding as obligate
heterodimers with the retinoid X receptor α (RXRα) and recruiting coactivators, including PGC-1α, in response to direct binding
and activation by FAs and their derivatives, which serve as ligands.
PPARα regulates genes involved in virtually every step of cardiac FA
utilization (reviewed in ref. 35). PPARα-null mice have reduced cardiac expression of genes involved in the cellular uptake, mitochondrial transport, and mitochondrial (and peroxisomal) oxidation of
FAs (36–38). Myocardial FA uptake and oxidation rates are decreased
in these mice, while glucose oxidation rates are increased (39).
PPARα-null mice have also provided evidence that PPARα serves
an important homeostatic function in the context of physiological
and dietary stressors. When subjected to fasting or pharmacological
inhibition of FAO, PPARα–/– mice develop massive cardiac myocyte
lipid accumulation and hepatic steatosis (40, 41). These results have
defined PPARα as an important regulator of myocardial energy substrate preference and FAO capacity within the PGC-1α transcriptional regulatory cascade.
In contrast to the biological function of PPARα, that of PPARβ
(also known as PPARδ) in the heart has not been extensively
studied. However, recent evidence indicates that cardiac PPARβ
target genes significantly overlap with those of PPARα. PPARβ
selective ligands induce mitochondrial FAO enzyme genes and
increase palmitate oxidation rates in cardiac myocytes from both
wild-type and PPARα–/– mice (42, 43). Consistent with findings
from activation studies, cardiac-specific deletion of the PPARβ
gene results in reduced expression of FAO enzyme genes and
diminished palmitate oxidation rates, which is similar to what
occurs in PPARα-null mice (44). In contrast to PPARα–/– mice,
however, cardiac-specific PPARβ-null mice do not exhibit a fasting-induced phenotype. Rather, PPARβ-deficient mice develop
a cardiomyopathy under basal conditions. Collectively, these
results suggest that, although PPARα and PPARβ drive similar
gene targets, PPARβ probably serves to regulate basal metabolism whereas PPARα is perhaps more important in the response
to physiological conditions that increase FA delivery.
The Journal of Clinical Investigation

ERRs are a subfamily of orphan nuclear receptors for which a
role in cardiac energy metabolism has recently been described.
There are 3 members of the ERR family: ERRα, ERRβ, and ERRγ
(45–47). Cardiac ERRα expression increases dramatically following birth, coincident with the switch to FAs as an energy substrate
and the upregulation of PPARα and PGC-1α and of enzymes
involved in FA uptake and mitochondrial oxidation (33, 48). Both
ERRα and ERRγ are directly coactivated by PGC-1α while ERRα is
further regulated by PGC-1α at the gene expression level (33, 34,
49, 50). Recent evidence suggests that ERRα cross-regulates other
transcription factors within the PGC-1α network. In cardiac myocytes, ERRα activates expression of many known PPARα and NRF
target genes involved in cellular FA utilization and mitochondrial
electron transport/oxidative phosphorylation, respectively (24).
This apparently overlapping function was recently shown to
occur, in part, via direct transactivation of the PPARα and Gabpa
(NRF-2 subunit) gene promoters. (Figure 2) (24, 51). In addition,
ERRα cooperates with NRF-1 and NRF-2 to regulate mitochondrial biogenesis and expression of oxidative phosphorylation
enzyme genes (51, 52). Collectively, these results support a role
for ERRα as an amplifier of cardiac oxidative energy metabolism
downstream of PGC-1α (Figure 2).
Signaling pathways trigger changes in mitochondrial function through
the PGC-1α regulatory cascade. How do PGC-1α and its transcription factor partners receive input from physiological and pathological stimuli? Insights into the physiological responsiveness
of the PGC-1α pathway come from identification of signal
transduction pathways that modulate the activity of PGC-1α and
its downstream partners (Figure 2). PGC-1α is upregulated in
response to β-adrenergic signaling, consistent with the involvement of this pathway in thermogenesis (8, 53). The stress-activated MAPK p38 activates PGC-1α by both increasing PGC-1α
protein stability and promoting dissociation of a repressor
(21, 54, 55). p38 also increases mitochondrial FAO through selective activation of the PGC-1α partner, PPARα (56). Conversely,
the ERK-MAPK pathway inactivates the PPARα/RXRα complex
via direct phosphorylation (57). Therefore, distinct limbs of the
MAPK pathway exert opposing regulatory influences on the
PGC-1α cascade. Recently, NO has emerged as a novel signaling
molecule proposed to integrate pathways involved in regulating
mitochondrial biogenesis. NO induces mitochondrial prolif-
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tricular hypertrophy due to hypertension or
imposed pressure overload have consistently
demonstrated a myocardial shift from FAO
toward glucose oxidation (67–72). Changes
in gene expression in the hypertrophied
heart, including downregulation of mitochondrial FAO enzymes, are consistent with
the observed metabolic alterations (73, 74).
The results of studies of energy substrate
shifts in the failing heart, particularly in
humans, have not led to a clear conclusion. Some investigators have shown that
expression of FAO genes and corresponding enzymatic activities are reduced in the
Figure 3
Cardiac energy substrate selection is a dynamic balance influenced by developmental, physi- failing rodent and human heart (70, 73, 75).
ological, and pathological cues. In the fetal heart, glucose oxidation is favored, whereas FA Consistent with these findings, recent caroxidation serves as the major ATP-generating pathway in the adult myocardium. Significant shifts diac positron emission tomography (PET)
in substrate preference occur in response to dietary (insulin) and physiological (exercise) stimuli. studies in humans have shown a shift away
Certain pathophysiological contexts, such as hypertrophy and ischemia, drive metabolism toward from FA utilization with hypertensive carglucose utilization, whereas in uncontrolled diabetes, the heart utilizes FAs almost exclusively.
diac hypertrophy and idiopathic cardioIn some cases, as in early response to pressure overload–induced hypertrophy, these metamyopathy (76, 77). However, others have
bolic shifts are thought to be protective. Alterations in activity or expression of nuclear receptors
demonstrated the opposite metabolic pro(PPARs and ERRs) and PGC-1α mediate these shifts in energy substrate utilization.
file or no change in substrate utilization in
humans and animal models of heart failure
eration and increases coupled respiration and ATP content in of mild-to-moderate severity (78–80). Animal models of failure
numerous cell types via a cGMP-dependent pathway (58, 59). The induced by pacing or myocardial infarction show that earlier stages
effects of NO/cGMP appear to be mediated, at least in part, by are not associated with a switch from FAs to glucose as the primary
energy substrate. Dogs with moderate severity coronary microemtranscriptional activation of PGC-1α expression levels (58).
Recent evidence has also implicated Ca2+ signaling in the bolism–induced heart failure exhibited FA and glucose uptake patcontrol of the PGC-1α/PPARα regulatory pathway. Transgenic terns that were indistinguishable from those of controls (81). These
mice overexpressing constitutively active calcineurin (Cn) or apparent discrepancies have been attributed to both the severity of
Ca2+/calmodulin-dependent kinase (CaMK) in skeletal muscle failure and temporal differences during the progressive remodeling
displayed increased PGC-1α expression and expansion of slow- that characterizes the transition to heart failure. The specific etioltwitch oxidative fibers and mitochondrial biogenesis (22, 60, 61). ogy of the myocardial disease may also play an important role.
Activation of PGC-1α by Cn and CaMK is mediated transcripSignificant progress has been made in delineating the gene
tionally through myocyte enhancer factor-2 (MEF-2) and cAMP regulatory events driving the reduction of myocardial FA utilizaresponse element–binding protein (CREB), respectively (62). In tion in the hypertrophied, failing, and hypoxic heart. Given the
the heart, exercise training activates the Cn and CaMK pathways importance of PPARα for the transcriptional control of cardiac
coincident with maintained or enhanced mitochondrial func- lipid metabolism, this nuclear receptor has served as an importion; however, paradoxically, overexpression of constitutively tant focus for such studies. In rodent models of pressure overload
activated forms of Cn or CaMK results in reduced mitochondrial hypertrophy, expression of PPARα and PGC-1α is reduced in the
oxidation and heart failure (63–65). Recent studies have shown hypertrophied and failing heart and in hypertrophied cardiac
that Cn and CaMK both activate PGC-1α expression in cardiac myocytes in culture (82–87). Levels of the PPAR partner, RXRα,
myocytes but have distinct effects on downstream targets of the are also reduced in a canine pacing-induced model of heart failure
PGC-1α pathway (66). CaMK activates genes involved in glucose and by hypoxia in cardiac myocytes (88, 89). Interestingly, a recipoxidation and mitochondrial electron transport while Cn selec- rocal induction of transcription factors, including chicken ovaltively activates mitochondrial FAO enzyme genes. The selective bumin upstream promoter-transcription factor (COUP-TF) and
effects of Cn are thought to be mediated, in part, through direct Sp1 and Sp3, which repress promoter activity of key FAO enzyme
transcriptional activation of the PPARα gene. Consistent with genes, is observed in hypertrophy and heart failure models and is
the gain-of-function results, reduction in Cn catalytic activity thought to contribute to the reduction in myocardial FAO (82, 90).
through cardiac-specific deletion of the CnB regulatory subunit Moreover, PPARα activity is inhibited posttranslationally in the
results in reduced PGC-1α and PPARα expression and downreg- hypertrophied cardiac myocyte in culture through ERK-MAPK–
dependent phosphorylation (83). The results of these studies
ulation of FAO enzymes (66).
suggest that one key mechanism involved in the energy substrate
switches in the hypertrophied and failing heart involves deactivaPerturbations in PGC-1/PPAR signaling
in the hypertrophied and failing heart
tion of the PGC-1α/PPARα complex at both transcriptional and
Numerous studies have demonstrated altered cardiac substrate posttranscriptional levels (Figure 3).
In contrast to heart failure related to pressure overload or ischpreference in the hypertrophied and failing heart. However, the
direction of the “fuel shifts” varies with the etiology and severity emia, the cardiomyopathy that develops in the context of insulin
of ventricular dysfunction. Studies using animal models of ven- resistance and frank diabetes is associated with increased cardiac
550
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reliance on FAs as the primary energy substrate (Figure 3) (91–94).
This fuel switch is linked to the combined effects of myocyte insulin resistance and high-circulating free FAs. We have found that,
consistent with this metabolic profile, the expression and activity
of PPARα, PGC-1α, and the enzymes of mitochondrial FAO are
induced in both insulin-deficient and insulin-resistant forms of
diabetes in mouse models (95, 96). The mechanism involved in the
activation of PPARα signaling in the diabetic heart is unknown
but likely involves increased cellular import of FAs, which serve as
ligands for this nuclear receptor. In contrast, other studies have
demonstrated a reduction in PPARα transcript levels in diabetic
myocardium (97, 98). This apparent discrepancy could reflect temporal-dependent regulatory events during progression of diabetic
myocardial disease. Future studies aimed at defining the precise
time-course of PPARα-driven regulatory events during the development of diabetic cardiomyopathy are needed.
Do derangements in mitochondrial energy
metabolism cause heart failure?
Myocardial fuel shifts as a cause of heart failure. Do deactivation of PGC-1α/
PPARα and the switch away from FAO in the hypertrophied heart
contribute to the pathological remodeling that leads to heart failure?
Similarly, does chronic activation of PPARα and myocardial FAO in
the diabetic heart lead to cardiac dysfunction? Alternatively, do these
myocardial substrate shifts serve adaptive functions in the diseased
heart? The answers to these questions have not been resolved, but
evidence provided largely by observations in rare genetic human diseases and genetically modified mice offers some insight. However,
perhaps the strongest evidence supporting deleterious effects of
reduced capacity for cardiac FA utilization comes from the observations of the cardiac phenotype of human genetic defects in FAO
pathway enzymes. Children with deficiencies in enzymes involved in
mitochondrial long-chain FAO often develop a stress-induced cardiomyopathy associated with myocardial lipid accumulation (99). In
addition, mouse models in which the FAO enzymes, very-long-chain
acyl-CoA dehydrogenase (VLCAD) or long-chain acyl-CoA dehydrogenase (LCAD), have been disrupted exhibit cardiomyopathies
similar to that observed in humans (100, 101). Furthermore, the
cardiomyopathic phenotype of mice with cardiac-specific deletion
of the PPARβ gene also supports the conclusion that a reduction in
capacity to oxidize FAs in the heart has deleterious effects (44). The
PPARβ–/– hearts accumulate lipids in association with the development of cardiac hypertrophy, which ultimately leads to dilated cardiomyopathy, myocyte apoptosis, and death.
One proposed mechanism for cardiac dysfunction in these models
is excess intracellular lipid accumulation resulting in myocyte dysfunction or death, termed “lipotoxicity” (reviewed in ref. 102). The
heart and other high-energy flux organs are adapted to closely match
energy substrate import and utilization, not storage. A mismatch can
result from increased lipid delivery, such as occurs in obesity or diabetes, or impaired FA oxidation, as in the aforementioned models.
The resulting derangements in cellular lipid homeostasis can lead to
accumulation of lipid intermediates such as acyl-CoA thioesters, acylcarnitines, ceramides, and triglycerides, molecules that could confer
cellular toxicity. Transgenic models in which proteins involved in FA
uptake/delivery are overexpressed also exhibit lipid accumulation
and systolic dysfunction (103, 104). These hearts display evidence of
myocyte dropout due to activation of apoptotic pathways. Indeed,
direct treatment with saturated long-chain FAs has been shown to
trigger apoptosis in cardiac myocytes as well as in other cell types in
The Journal of Clinical Investigation

culture via mechanisms that may involve generation of reactive oxygen species (105–107). Collectively, observations in mice and humans
indicate that severe reduction in mitochondrial FAO capacity sets the
stage for cardiac lipotoxic effects related to lipid intermediates that
accumulate in the context of impaired catabolism.
Despite compelling evidence for the deleterious effects of
reduced mitochondrial FAO in genetic models and human deficiency states, there is some data to suggest that a shift from FAO
to glucose utilization in the hypertrophied heart may be adaptive,
at least in the short term. Taegtmeyer and coworkers have shown
that reactivation of FAO in a rat ventricular-pressure overload
model causes ventricular dysfunction (108). In addition, despite
reduced cardiac FAO rates, PPARα-null mice do not exhibit
overt ventricular dysfunction (39). It is likely that the degree and
duration of the pathophysiological stimulus as well as the systemic metabolic state (e.g., levels of circulating lipids) ultimately
determine whether alterations in FAO capacity contribute to the
pathogenesis of heart failure.
As described above, the insulin resistant and diabetic heart
is characterized by increased FAO rates due, perhaps in part,
to chronic activation of the PPARα gene regulatory pathway.
Studies of mice genetically modified to mimic the metabolic
derangements of the diabetic heart have provided evidence that
chronically increased reliance on FAs for energy leads to pathological signatures of the diabetic heart. Mice with cardiac-specific
overexpression of PPARα (MHC-PPARα mice) exhibit increased
expression of PPARα target genes involved in cellular FA import
and peroxisomal and mitochondrial FAO, coincident with lipid
accumulation and increased rates of FAO (96, 109). Interestingly,
myocardial glucose uptake and oxidation rates are reciprocally
decreased in the MHC-PPARα mouse, a metabolic phenotype that
mimics the diabetic heart. These results demonstrate that a primary drive on the PPARα gene regulatory pathway triggers cross-talk
suppression of glucose utilization pathways. Importantly, the metabolic derangements of MHC-PPARα mice are associated with ventricular diastolic/systolic dysfunction at baseline, which becomes
more severe in the context of increased delivery of FAs to the heart
such as occurs with high-fat feeding or insulinopenia (95). Thus,
restricting the heart to reliance on FAs to the virtual exclusion of
glucose oxidation leads to development of cardiomyopathy (109).
The metabolic dysregulation in the MHC-PPARα heart is associated with neutral lipid accumulation and increased production of
reactive species consistent with the importance of oxidative stress
and mitochondrial dysfunction in diabetic cardiomyopathy (95).
Direct characterization of mitochondria from hearts in type 1 diabetic models has revealed evidence of damaged mitochondria and
impaired mitochondrial respiration, presumably due to oxidative
stress (110). In the same type 1 model, overexpression of antioxidant proteins such as metallothionein and catalase reduced reactive oxygen species and rescued cardiac contractility (111–113). A
similar effect was observed with catalase overexpression in a mouse
model of type 2 diabetes (112). The observations from elevated FA
flux and FAO-deficient states, which indicate that either a chronic
increase (diabetes) or decrease (pressure overload hypertrophy) in
myocardial FAO can lead to heart failure, emphasize the importance
of substrate flexibility for normal cardiac function (Figure 3).
Derangements in mitochondrial ATP generation. Evidence for a link
between mitochondrial respiratory dysfunction and heart failure is compelling. The cardiomyopathic phenotype of humans
with mitochondrial genome defects underscores the importance
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of high-capacity mitochondrial ATP production for normal
striated-muscle function. Mutations in both nuclear- and mitochondrial-encoded genes account for heritable respiratory chain
defects (for an extensive review of this topic, see refs. 114–117).
Respiratory chain defects typically present as multisystem dysfunction disproportionately affecting organs with high ATP
demand, such as the heart, skeletal muscle, and the central nervous system. Cardiomyopathy may develop during childhood
or at later ages. Mouse models of mitochondrial dysfunction
have also provided important information about the role of
mitochondrial proteins in regulating mitochondrial number
and function as well as the way in which altered mitochondrial
energetics contribute to the development of heart failure. Tfam
is a nuclear-encoded mitochondrial transcription factor necessary for mitochondrial biogenesis and gene expression. Cardiacspecific Tfam–/– mice exhibit reduced respiratory capacity and
mitochondrial DNA in the heart before birth coincident with a
high neonatal mortality (118). Surviving animals develop hypertrophy, progressing to dilated cardiomyopathy and conduction
abnormalities, and die by 4 months of age. Interestingly, cardiac
dysfunction is accompanied by a metabolic shift from FAO to
glucose oxidation (119).
Adenine nucleotide translocators (Ants) are mitochondrial-membrane proteins involved in the transport of cytoplasmic ADP in
exchange for mitochondrial ATP, so mitochondria deficient in Ant
have reduced capacity for substrate level phosphorylation. Mice
targeted for the Ant1 gene, the cardiac/skeletal muscle expressed
isoform, exhibit reduced ADP-dependent respiration rates in heart
and skeletal muscle in spite of increased mitochondrial number
(120, 121). The mitochondrial proliferation is likely a compensatory response to cellular energy deficiency but is thought to contribute to progressive cardiac hypertrophy that develops in these
mice (121, 122). ATP deficiency is thought to be a primary cause
for the observed pathophysiology, but these models also support a
role for mitochondrial-derived ROS in mediating cellular damage
(123). Although the precise cellular insults are still unknown, these
genetic models demonstrate that mitochondrial dysfunction is sufficient for the development of heart failure.
Several recently developed mouse models have identified exciting
potential links between PGC-1α–mediated control of mitochondrial function and the development of heart failure. Sano et al. recently found that overexpression of cyclin T/Cdk9, an RNA polymerase
kinase, triggers cardiac hypertrophy (124). Further studies revealed
that in the context of ventricular pressure overload, mice overexpressing Cdk9 in the heart develop a fulminant apoptotic cardiomyopathy (125). Gene expression–profiling studies demonstrated
that Cdk9 suppresses expression of PGC-1α and its downstream
targets involved in mitochondrial respiratory function. Rescue of
PGC-1α expression in cardiac myocytes in culture prevented Cdk9triggered apoptosis. In a separate mouse model, chronic activation
of PGC-1α in the heart, as occurs in diabetes, led to ventricular dysfunction. In a study using an inducible, cardiac-specific transgenic
system, chronic overexpression of PGC-1α protein in the adult
mouse heart caused mitochondrial ultrastructural abnormalities
and reduced myofibrillar density, which led to cardiomyopathy
and diastolic dysfunction (25). Interestingly, the mitochondrial
proliferative response is reversible and the cardiomyopathy rescued
upon cessation of transgene expression. The basis for this reversible cardiomyopathy is unknown but could involve the accumulation of reactive intermediates or abnormalities in ATP generation.
552
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Taken together, these recent findings suggest that, in the context
of a mechanical stress such as pressure overload, reduced levels of
PGC-1α predispose the heart to pathological remodeling related
to mitochondrial dysfunction and apoptosis. Conversely, chronic
activation of PGC-1α and its downstream targets, such as PPARα,
that mimic the diabetic state also leads to ventricular dysfunction
through mechanisms that are reversible.
Despite strong evidence for a link between mitochondrial dysfunction and heart failure in genetic models, the role of altered
mitochondrial ATP generation in the pathogenesis of acquired
forms of heart failure is less clear. Phosphocreatine (pCR) serves
as the main energy store in myocardium (for review, see ref. S1;
see Supplemental References; supplemental material available
online with this article; doi:10.1172/JCI200524405DS1). Early
studies revealed that myocardial pCR/ATP ratios are reduced in
the hypertrophied and failing heart while absolute ATP levels are
only detectably reduced in heart failure (S2–S4). However, the
concentration of ATP measured in the failing myocardium is still
above the Km for most cellular ATPases. Consistent with a gradual fall in intracellular high-energy phosphates, the “energy sensor
kinase,” AMP-activated protein kinase (AMPK), is upregulated
and activated during hypertrophy (S5). These results suggest that
myocardial energy reserves are disproportionately reduced during
hypertrophy and heart failure progression compared to absolute
ATP levels. In dog models of pacing-induced heart failure, ATP
concentrations fall gradually coincident with a reduction in mitochondrial respiration rates during the progression to heart failure
(S6, S7). These functional changes are associated with evidence of
structural abnormalities in mitochondria from these hearts (S8).
Reduced mitochondrial oxidative capacity has also been observed
in rodent heart failure models (87). Further studies will be necessary to accurately delineate the temporal pattern of alterations
in bioenergetics during the development of heart failure. Murine
genetic loss-of-function and pharmacological rescue strategies in
larger animal models should serve as useful experimental strategies to determine cause-and-effect relationships.
Metabolic modulators as a new treatment strategy
for heart failure? A question of balance
In summary, evidence is emerging to support the concept that
alterations in myocardial fuel selection and energetics are linked
to the development and progression of heart failure. Accordingly,
metabolic pathways involved in cardiac FA and glucose utilization or ATP generation are attractive targets of novel therapeutic
strategies aimed at the prevention or early treatment of heart failure. Indeed, specific activators for each of the PPARs have been
developed and are currently used for treatment of hyperlipidemia
(e.g., fibrates) and diabetes (thiazolidinediones). Activation of the
PPAR pathway in heart or extracardiac tissues, such as adipose or
liver, could theoretically reduce cardiac lipotoxicity by reducing
lipid delivery or increasing mitochondrial oxidation. However,
a strong word of caution is necessary. As described above, it is
now clear that the degree of metabolic modulation is an important determinant of whether shifts in energy substrate utilization
serve adaptive or maladaptive functions in the context of disease states that predispose patients to heart failure. Conversely,
chronic activation of PPARα could lead to deleterious effects, particularly in the context of diabetes, hyperlipidemic states, or the
ischemic heart, given the potential for increased mitochondrial
oxidative flux, which could generate ROS and increase oxygen
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consumption. It is likely that the response will be disease-specific
and dependent on the systemic metabolic phenotype. Studies in
large animals and humans will be particularly informative. Such
studies will require rigorous metabolic phenotyping approaches
with imaging modalities such as PET and spectroscopy to define
baseline myocardial substrate utilization and energetic profiles,
respectively. Similarly, both metabolic and functional endpoints
will be necessary to assess response to therapy. If metabolic modulator therapy proves useful, the standard diagnostic approach to
the heart failure patient will likely include metabolic imaging or
surrogate metabolic biomarkers to guide therapeutic decisions
and assess the patient’s response. In this regard, an interdisciplinary approach involving cardiologists, endocrinologists, and radiologists might be envisioned.
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